Stent Thrombosis
At Issue: Debate over DAPT duration endures
Since the advent of drug-eluting stents, there has been a debate in the intervention community over how long dual antiplatelet therapy should last after PCI.
FDA grants premarket approval to carotid stenting system for stroke
The FDA has granted premarket approval to the Neuroguard IEP System, a novel stenting system intended to ease the process for individuals with stroke, according to the manufacturer.
Edoxaban reduced clinical events with less bleeding vs. dual therapy for AF, stable CAD
Edoxaban monotherapy for patients with atrial fibrillation and stable coronary disease reduced risk for adverse clinical events, mainly driven by lower bleeding risk, compared with dual antiplatelet therapy, a speaker reported.
FDA approves drug-coated balloon for the treatment of coronary in-stent restenosis
Boston Scientific announced the FDA approval of its drug-coated balloon indicated for the treatment of coronary in-stent restenosis in patients with coronary artery disease.
Triple drug-coated stent may reduce risk for stent thrombosis, target lesion failure
SAN FRANCISCO — The first-time application of a triple-drug, site-specific antithrombotic therapy on a stent platform was safe and effective for managing thrombotic and bleeding risk after PCI, data presented at TCT 2023 show.
BIOSTEMI: 5-year data show superiority for biodegradable SES vs. durable EES
SAN FRANCISCO — A biodegradable polymer sirolimus-eluting stent remained superior to a durable polymer everolimus-eluting stent for treating STEMI at 5 years, a difference driven by lower rates of ischemia-driven repeat revascularizations.
Drug-coated balloon bests uncoated balloon for coronary in-stent restenosis in AGENT IDE trial
SAN FRANCISCO — A paclitaxel-coated balloon was superior to conventional balloon angioplasty for treatment of coronary in-stent restenosis, according to the results of the AGENT IDE trial presented at TCT 2023.
Stopping aspirin 1 month after drug-eluting stent implantation feasible for patients with ACS
SAN FRANCISCO — In patients with ACS, stopping aspirin for ticagrelor monotherapy within 1 month of receiving a drug-eluting stent did not increase adverse CV and bleeding events compared with 12 months of dual antiplatelet therapy.
World’s first minimally invasive deep venous ‘stent cleaner’ shows real-world promise
In March, Steven Abramowitz, MD, a surgeon at MedStar Washington Hospital Center, completed the world’s first procedures to treat deep venous stent thrombosis using a novel minimally invasive thrombectomy catheter.
5-year data show titanium-nitride-oxide coated stents may be safer than DES
In patients with ACS, there were no differences in 5-year risk for cardiac death, MI or target lesion revascularization for those who received titanium-nitride-oxide-coated stents vs. biodegradable polymer drug-eluting stent, data show.